John Hussman's PTGX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 12,600 shares of Protagonist Therapeutics, Inc. (PTGX) worth $1.1 M, representing 0.27% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, John Hussman has maintained this position in PTGX for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q1 2025, reducing 52,500 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -8,400 | Reduce 40.00% | 12,600 | $87.34 |
| Q3 2025 | -10,500 | Reduce 33.33% | 21,000 | $66.43 |
| Q2 2025 | -21,000 | Reduce 40.00% | 31,500 | $55.27 |
| Q1 2025 | -52,500 | Reduce 50.00% | 52,500 | $48.36 |
| Q4 2024 | +105,000 | New Buy | 105,000 | $38.60 |
John Hussman's Protagonist Therapeutics Investment FAQs
John Hussman first purchased Protagonist Therapeutics, Inc. (PTGX) in Q4 2024, acquiring 105,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Protagonist Therapeutics, Inc. (PTGX) for 5 quarters since Q4 2024.
John Hussman's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q4 2024, adding 105,000 shares worth $4.05 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 12,600 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $1.1 M.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.27% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 105,000 shares, as reported at the end of Q4 2024.